Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

Trial Profile

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

Phase of Trial: Phase III

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Apr 2016 Primary endpoint (Change in Mean Weekly Glucose Concentrations From Baseline at 12 Weeks) for 1.2 mg and 1.8 mg dose of Liraglutide has been met, according to results published in the Diabetes Care.
    • 05 Apr 2016 Results analyzing efficacy of Liraglutide published in the Diabetes Care,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top